Global Hemophilia Treatment Market: Share, Size, Growth,Opportunities, and Forecast 2019-2027

 

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of clotting factor, factor VIII. There are approximately 13 different types of clotting factors that work with blood platelets to aid clotting. Hemophilia A, B, and C are the three types. Hemophilia A is the most common type and is caused by factor VIII deficiency. Hemophilia B is caused by a factor IX deficiency, while Hemophilia C is caused by a factor XI deficiency.

Novel product launches by hemophilia treatment market players are expected to drive market growth over the forecast period. For example, Novo Nordisk received marketing authorization from the European Commission for 'Esperoct' in Europe in June 2019.

Hemophilia Treatment Market is an inherited genetic disorder that impairs the body's ability to form blood clots. It happens when there is a mutation or change in one of the genes that provide instructions for making the clotting factor proteins required to form a blood clot. As a result, people with this condition (hemophilia) experience excessive bleeding following any injury or damage.

Because hemophilia is a genetic disorder, there is currently no permanent cure for this medical condition. People with Hemophilia Treatment Market, on the other hand, use various hemophilia treatment therapies to replace the missing factor proteins required for blood clotting. The adoption of hemophilia treatments such as replacement therapy and gene therapy significantly improves patients' quality of life.

Hemophilia Treatment Market consists of a variety of therapies or medications used to improve blood clotting. These therapies work by simulating the activities of missing or insufficient factor proteins required for blood clotting.

Demand for hemophilia treatments such as replacement therapy has risen significantly over the years due to their high efficacy, and this trend is expected to continue during the forecast period. Concentrates of clotting factor VII (for hemophilia A) or clotting factor IX (for hemophilia B) are slowly injected into a vein, where they replace the missing proteins.

Key Players

Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, F. Hoffmann-La Roche AG are among the major players in the global hemophilia treatment market.